STOCK TITAN

Cerevel Therapeutics Holdings Inc - CERE STOCK NEWS

Welcome to our dedicated news page for Cerevel Therapeutics Holdings (Ticker: CERE), a resource for investors and traders seeking the latest updates and insights on Cerevel Therapeutics Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cerevel Therapeutics Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cerevel Therapeutics Holdings's position in the market.

Rhea-AI Summary
Cerevel Therapeutics announces positive topline results for tavapadon in a Phase 3 adjunctive trial for people living with Parkinson’s disease. The pivotal TEMPO-3 trial showed a significant increase in 'on' time without dyskinesia compared to placebo. Tavapadon demonstrated potential for motor control, safety, and tolerability. Additional data will be presented at future medical meetings, with Phase 3 monotherapy trial results expected in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
-
Rhea-AI Summary
AbbVie Inc. (NYSE: ABBV) is set to acquire Cerevel Therapeutics (NASDAQ: CERE) for a total equity value of approximately $8.7 billion. The acquisition adds a robust neuroscience pipeline to AbbVie's portfolio, focusing on psychiatric and neurological disorders. The transaction is expected to close in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
-
Rhea-AI Summary
Cerevel Therapeutics (Nasdaq: CERE) to Host Tavapadon Investor Webcast for Phase 3 Development in Parkinson’s Disease Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
conferences
Rhea-AI Summary
Cerevel Therapeutics (Nasdaq: CERE) to participate in two investor conferences in November with President and CEO Ron Renaud joining fireside chats. Live webcasts and archived versions will be available on the company's investor section website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
conferences
-
Rhea-AI Summary
Cerevel Therapeutics reported financial results for Q3 2023, raising $499 million from a public offering of common stock. The company's data readout timelines for emraclidine, darigabat, and tavapadon remain on track. Cerevel is well-capitalized with operations supported into 2026. Tavapadon investor webcast scheduled for December 11, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.19%
Tags
-
Rhea-AI Summary
Cerevel Therapeutics to report Q3 2023 financial results and business updates on November 1, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.54%
Tags
conferences earnings
Rhea-AI Summary
Cerevel Therapeutics announces pricing of public offering of common stock
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
-
Rhea-AI Summary
Cerevel Therapeutics announces $400 million public offering of common stock
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
-
Rhea-AI Summary
Cerevel Therapeutics to participate in Morgan Stanley healthcare conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.09%
Tags
Cerevel Therapeutics Holdings Inc

Nasdaq:CERE

CERE Rankings

CERE Stock Data

7.60B
77.23M
15.33%
86.57%
5.3%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About CERE

cerevel therapeutics is a biopharmaceutical company focused on developing new therapies to treat disorders of the central nervous system (cns). the company has a portfolio of experimental neuroscience therapies, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of cns disorders, including parkinson’s, alzheimer’s, epilepsy, schizophrenia and addiction. headquartered in the greater boston area, cerevel was formed in 2018 through a partnership between bain capital and pfizer.